SCHEMBL27006405

SCHEMBL27006405

COc1cc(O)c(CC=C(C)C)c2c1C(=O)C(O)C(c1ccc(O)cc1)O2

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ESR1 P03372 4/20 0.68
▸ AKR1B10 O60218 2/20 0.68
▸ AKR1B1 P15121 2/20 0.68
▸ PDPK1 O15530 2/20 0.68
▸ PRKCA P17252 1/20 0.68
▸ BACE1 P56817 1/20 0.68
▸ PRKCQ Q04759 1/20 0.68
▸ ABCG2 Q9UNQ0 4/20 0.55
▸ ESR2 Q92731 2/20 0.55
▸ CACNA1G O43497 2/20 0.55
▸ CACNA1H O95180 2/20 0.55
▸ MAOA P21397 1/20 0.55
▸ PDE5A O76074 1/20 0.55
▸ ACHE P22303 4/20 0.53
▸ CYP19A1 P11511 1/20 0.52
▸ PDCD1 Q15116 1/20 0.50
▸ CD274 Q9NZQ7 1/20 0.50
▸ CYP3A4 P08684 1/20 0.48
▸ CYP2D6 P10635 1/20 0.48
▸ CYP2C9 P11712 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27013475 1.00 ESR1 (0.68) ESR1AKR1B10AKR1B1PDPK1PRKCA
Neophellamuretin SCHEMBL27013455 0.88 ABCG2 (0.66) ESR1AKR1B10AKR1B1PDPK1PRKCA
Neophellamuretin SCHEMBL30766255 0.88 ABCG2 (0.66) ESR1AKR1B10AKR1B1PDPK1PRKCA
SCHEMBL13111972 0.87 PDPK1 (0.51) ESR1AKR1B10AKR1B1PDPK1PRKCA
SCHEMBL28910074 0.84 BACE1 (0.48) ESR1AKR1B10AKR1B1PDPK1PRKCA
SCHEMBL34461906 0.81 ESR1 (0.56) ESR1AKR1B10AKR1B1PDPK1PRKCA
Isoxanthohumol SCHEMBL29743582 0.81 ESR1 (1.00) ESR1AKR1B10AKR1B1PDPK1PRKCA
Isoxanthohumol SCHEMBL904557 0.81 ESR1 (1.00) ESR1AKR1B10AKR1B1PDPK1PRKCA
Isoxanthohumol SCHEMBL14092988 0.81 ESR1 (1.00) ESR1AKR1B10AKR1B1PDPK1PRKCA
Isoxanthohumol SCHEMBL30033683 0.81 ESR1 (1.00) ESR1AKR1B10AKR1B1PDPK1PRKCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240016777-A1 COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS BETH ISRAEL DEACONESS MEDICAL CENTER, INC. 2024-01-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240016777-A1 COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS THPO, SERPINB1, SERPINC1 ESR1 4309/4885AKR1B10 2359/4885AKR1B1 1479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback